Target
In this study, a lactic acid-responsive promoter was used to control the expression of anti-PD-L1 antibody protein or azurin killer protein. EcN was designed as a tumor-specific drug delivery carrier that utilized the tumor targeting of bacteria to track tumors and locally release drugs that inhibit tumor growth, thereby reducing drug dosage and drug cost. Our research will provide new ideas for cancer treatment.